Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program

Date

21 Oct 2023

Session

Poster session 20

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Maria Lucia Reale

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

M.L. Reale1, F. Passiglia2, M. Brambilla3, G. Pasello4, G. Minuti5, A. Bulotta6, P. Pizzutilo7, C. Sini8, J. Costa9, E. Roca10, E. Bria11, S. Pilotto12, C. Genova13, G. Metro14, F. Citarella15, P. Bordi16, A. Russo17, R. Chiari18, K. Andrikou19, S. Novello2

Author affiliations

  • 1 Department Of Oncology, Vito Fazzi Hospital- ASL Lecce, 73100 - Lecce/IT
  • 2 Department Of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 - Orbassano/IT
  • 3 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4 Department Of Surgery, Oncology And Gastroenterology, University of Padova Medical School, Padova, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 - Padova/IT
  • 5 Department Of Medical Oncology, IRCCS Regina Elena National Cancer Institute, 00144 - Roma/IT
  • 6 Department Of Oncology, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 7 Medical Thoracic Oncology Unit, Istituto Tumori Giovanni Paolo II, 70124 - Bari/IT
  • 8 Medical Oncology, Ospedale Giovanni Paolo II - ATS Sardegna - ASSL Olbia, 07026 - Olbia/IT
  • 9 Santa Maria Della Misericordia Hospital, University of Udine - Dipartimento di Area medica - DAME, 33100 - Udine/IT
  • 10 Thoracic Oncology, Lung Unit, P. Pederzoli Hospital, Peschiera del Garda/IT
  • 11 Translational Medicine And Surgery Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 - Rome/IT
  • 12 Department Of Engineering For Innovation Medicine University Of Verona, Section of Oncology, 37100 - Verona/IT
  • 13 Lung Cancer Unit, Università degli Studi di Genova e Ospedale Policlinico San Martino IRCCS - DiMI, 16132 - Genova/IT
  • 14 Medical Oncology Department, Ospedale S. Maria della Misericordia, 06156 - Perugia/IT
  • 15 Oncology Department, Policlinico Universitario Campus Bio-Medico, 00128 - Rome/IT
  • 16 Medical Oncology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 17 Medical Oncology Unit, Centro Oncologico Ospedale Papardo, 98158 - Messina/IT
  • 18 Uoc Oncologia, AST Pesaro Urbino, 61122 - Pesaro/IT
  • 19 Department Of Medical Oncology, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1403P

Background

Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality of life over docetaxel in patients with KRAS p.G12C–mutated advanced non–small-cell lung cancer (NSCLC) in the CodeBreak-200 study. Here we report real-world efficacy and tolerability data from NSCLC patients who received sotorasib within the Italian expanded access program (EAP).

Methods

Sotorasib (960 mg, orally, once daily) was available on physician request for KRAS p.G12C mutant advanced NSCLC patients who were pretreated with standard regimens or unfit for approved therapies. Clinical-pathological and molecular data were collected from the Italian ATLAS real-word registry. Patients underwent CT-scan and responses were evaluated by RECIST criteria. Efficacy and tolerability outcomes have been assessed.

Results

A total of 190 advanced NSCLC patients were treated across 30 Italian centres. The overall patients’ median age was 68 years old (range 32-85). Most patients were male (62%), former (49%) or current smokers (42%), with ECOG performance status 0/1 (84%) and adenocarcinoma subtype (89%). Tumor PD-L1 expression was ≥ 50%, 1-49% and <1% in 25%, 37% and 31% of patients, respectively. Patients had received a median of 2 (0–4) previous lines of systemic therapy, with 44% and 33% of them receiving sotorasib in 2nd and 3rd line, respectively. Overall, response rate was 26% and disease control rate 66%. Median PFS was 6.1 months (95% CI: 5.6 – 9.1). Median overall survival (OS) was 8.2 months (95% CI: 6.7-13.6) without significant differences across the main clinical subgroups [age (< 70 vs ≥ 70 years, p= 0.83), treatment line (1st/2nd vs >2nd, p=0.3), brain metastases (p=0.53)]. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 32 patients (17%), with no significant differences between who received or not previous immunotherapy (16% vs 14%, respectively). The most common TRAEs were hepatotoxicity (12%), diarrhea (3%) and asthenia (1%).

Conclusions

Real-world data from the Italian EAP confirm the activity and tolerability of sotorasib in pre-treated patients with KRAS p.G12C-mutated advanced NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

F. Passiglia: Financial Interests, Advisory Board: AstraZeneca, Janssen, Amgen, Sanofi, Roche, MSD, BMS, BeiGene, Thermo Fisher Scientific. G. Minuti: Financial Interests, Advisory Board: Roche, BMS, AstraZeneca, Gilead, Novartis, Sanofi. E. Bria: Financial Interests, Advisory Board: MSD Oncology, AstraZeneca, Pfizer, Lilly, Bristol Myers Squibb, Roche. S. Pilotto: Financial Interests, Advisory Board: AstraZeneca, Eli Lilly & Co, Boehringer Ingelheim, Merck Sharp and Dohme, Roche, Bristol-Myers Squibb. C. Genova: Financial Interests, Advisory Board: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Merck-Sharp-Dohme, Roche, Takeda. R. Chiari: Financial Interests, Advisory Board: Takeda. S. Novello: Financial Interests, Advisory Board: Boehringer Ingelheim, AstraZeneca, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Eli Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.